InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $1.820 0.12 (7.06%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$1,790 Change of Director's Interest Notice RH 27 Mar 2026 1:17PM $1.113 $1.820 risen by 63.60%
$1,790 PKD - Presentation at World Congress of Nephrology 27 Mar 2026 9:58AM $1.170 $1.820 risen by 55.56%
$1,790 ADOA Program - Presentation at NANOS 2026 24 Mar 2026 9:01AM $1.200 $1.820 risen by 51.67%
$1,790 Regulatory Alignment on Registrational Trial Requirements 16 Mar 2026 9:19AM $1.415 $1.820 risen by 28.62%
$1,790 Change of Director's Interest Notice RH IC 10 Mar 2026 6:41PM $1.470 $1.820 risen by 23.81%
$1,790 Application for quotation of securities - PYC 9 Mar 2026 7:55PM $1.480 $1.820 risen by 22.97%
$1,790 Application for quotation of securities - PYC 6 Mar 2026 9:46AM $1.485 $1.820 risen by 22.56%
$1,790 Joint Company Secretary Appointment 4 Mar 2026 7:11PM $1.470 $1.820 risen by 23.81%
$1,790 Completion of Retail Entitlement Offer 4 Mar 2026 9:29AM $1.485 $1.820 risen by 22.56%
$1,790 PKD Clinical Trial - Approval to Escalate Dosing 27 Feb 2026 8:04AM $1.495 $1.820 risen by 21.74%
$1,790 Change in substantial holding 25 Feb 2026 9:35AM $1.490 $1.820 risen by 22.15%
$1,790 2026 Q1 Investor Update 24 Feb 2026 9:18AM $1.500 $1.820 risen by 21.33%
$1,790 Half Yearly Report and Accounts 23 Feb 2026 6:47PM $1.500 $1.820 risen by 21.33%
$1,790 Application for quotation of securities - PYC 18 Feb 2026 9:47AM $1.490 $1.820 risen by 22.15%
$1,790 Becoming a substantial holder 13 Feb 2026 12:29PM $1.485 $1.820 risen by 22.56%
$1,790 Cleansing Notice under Section 708A(5)(e) 12 Feb 2026 11:39AM $1.495 $1.820 risen by 21.74%
$1,790 Application for quotation of securities - PYC 11 Feb 2026 11:45AM $1.495 $1.820 risen by 21.74%
$1,790 Despatch of Retail Offer Booklet 9 Feb 2026 1:32PM $1.475 $1.820 risen by 23.39%
$1,790 Notification to Ineligible Retail Shareholders 9 Feb 2026 9:23AM $1.500 $1.820 risen by 21.33%
$1,790 Retail Offer Booklet 9 Feb 2026 9:21AM $1.500 $1.820 risen by 21.33%
$1,790 Investor Webinar 5 Feb 2026 12:09PM $1.495 $1.820 risen by 21.74%
$1,790 Completion of Placement and Institutional Entitlement Offer 4 Feb 2026 9:39AM $1.600 $1.820 risen by 13.75%
$1,790 Proposed issue of securities - PYC 2 Feb 2026 10:05AM $1.600 $1.820 risen by 13.75%
$1,790 Notice Under Section708AA(2)(f) 2 Feb 2026 9:40AM $1.600 $1.820 risen by 13.75%
$1,790 PYC Capital Raising Presentation 2 Feb 2026 9:40AM $1.600 $1.820 risen by 13.75%

26 - 50 of 929 results

Page 2 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.